Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Neutral

B

BridgeBio Pharma, Inc. Common Stock (BBIO)

Pharmaceutical Preparations

https://www.bridgebio.com

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

3160 PORTER DR., SUITE 250
PALO ALTO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/27/2019

Market Cap

4,599,287,180

Shares Outstanding

173,970,000

Weighted SO

173,967,052

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

ISEE --.--%

BPMC --.--%

AMLX --.--%

KRTX --.--%

DAWN --.--%

MRTX --.--%

TERN --.--%

APLS --.--%

CERE --.--%

Beta

1.0600

Last Div

0.0000

Range

21.62-44.32

Chg

-0.5000

Avg Vol

1905229

Mkt Cap

4599287180

Exch

NASDAQ

Country

US

Phone

650 391 9740

DCF Diff

33.5426

DCF

-9.0726

Div Yield

0.0000

P/S

20.9894

EV Multiple

-11.7348

P/FV

-4.1982

Div Yield %

0.0000

P/E

-10.1106

PEG

0.5645

Payout

0.0000

Current Ratio

4.5863

Quick Ratio

4.5863

Cash Ratio

4.0738

DSO

1.0994

DIO

0.0000

Op Cycle

1.0994

DPO

1333.3313

CCC

-1332.2319

Gross Margin

0.9774

Op Margin

-2.3001

Pretax Margin

-2.0948

Net Margin

-2.0711

Eff Tax Rate

-0.0298

ROA

-0.5713

ROE

0.3859

ROCE

-0.7636

NI/EBT

0.9886

EBT/EBIT

0.9108

EBIT/Rev

-2.3001

Debt Ratio

2.1680

D/E

-1.5758

LT Debt/Cap

2.7496

Total Debt/Cap

2.7367

Int Coverage

-1016.1552

CF/Debt

-0.2409

Equity Multi

-0.7268

Rec Turnover

332.0061

Pay Turnover

0.2738

Inv Turnover

0.0000

FA Turnover

12.8090

Asset Turnover

0.2758

OCF/Share

-2.2117

FCF/Share

-2.2373

Cash/Share

3.1302

OCF/Sales

-1.8934

FCF/OCF

1.0116

CF Coverage

-0.2409

ST Coverage

-89.7424

CapEx Coverage

-86.3432

Div&CapEx Cov

-86.3432

P/BV

-4.1982

P/B

-4.1982

P/S

20.9894

P/E

-10.1106

P/FCF

-10.9589

P/OCF

-11.0595

P/CF

-11.0595

PEG

0.5645

P/S

20.9894

EV Multiple

-11.7348

P/FV

-4.1982

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Mar 21, 20:00 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Nov 23, 00:11 Attruby™ (acoramidis), a Near Complete TTR Stabilizer (?90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients GlobeNewswire Inc. Jan 10, 07:30 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Jan 03, 16:30 BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference GlobeNewswire Inc. Jan 03, 07:30 BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON) The Motley Fool Jan 03, 06:45 2 Biotechs That Could Get Bought Out in 2024 MarketWatch Dec 28, 09:40 The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023 MarketWatch Dec 28, 09:40 The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023 MarketWatch Dec 28, 04:52 The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023 MarketWatch Dec 27, 14:46 The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023 MarketWatch Dec 27, 14:46 The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023 GlobeNewswire Inc. Dec 13, 07:30 BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia GlobeNewswire Inc. Dec 08, 07:30 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Dec 05, 07:44 BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) GlobeNewswire Inc. Nov 12, 10:30 BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) GlobeNewswire Inc. Nov 12, 10:30 BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) GlobeNewswire Inc. Nov 12, 10:30 BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) GlobeNewswire Inc. Nov 12, 10:30 BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) GlobeNewswire Inc. Nov 12, 10:30 BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) GlobeNewswire Inc. Nov 12, 10:30 BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Revenue Product Segmentation